-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
-
Summary
-
Revance Therapeutics, Inc. quarterly/annual Amortization of Intangible Assets history and growth rate from 2019 to 2023.
- Revance Therapeutics, Inc. Amortization of Intangible Assets for the quarter ending June 30, 2024 was $546K, unchanged year-over-year.
- Revance Therapeutics, Inc. Amortization of Intangible Assets for the twelve months ending June 30, 2024 was $6.13M, a 65.5% decline year-over-year.
- Revance Therapeutics, Inc. annual Amortization of Intangible Assets for 2023 was $6.13M, a 76.2% decline from 2022.
- Revance Therapeutics, Inc. annual Amortization of Intangible Assets for 2022 was $25.8M, a 60.9% increase from 2021.
- Revance Therapeutics, Inc. annual Amortization of Intangible Assets for 2021 was $16M, a 123% increase from 2020.
Amortization of Intangible Assets, Trailing 12 Months (USD)
Amortization of Intangible Assets, Annual (USD)
Amortization of Intangible Assets, YoY Annual Growth (%)